FDA Home Page | Search FDA Site | FDA A-Z Index | Contact FDA

Peripheral and Central Nervous System Drugs Advisory Committee

Amended Notice
To reflect changes in the Date, Time, and Procedure portions of the meeting.

Background material and meeting information will become available no later than one business day before each meeting day (Simply scroll down to the appropriate committee heading).

Notice:
The Food and Drug Administration (FDA) is announcing an amendment to the notice of meeting of the Peripheral and Central Nervous System Drugs Advisory Committee. This meeting was announced in the Federal Register of January 27, 2006 (71 FR 4593). The amendment is being made to reflect a change in Date and Time and Procedure portions of the document. An additional day is being added to this meeting and the length of time allotted for the open public hearing portion is being extended. There are no other changes.

Supplementary Information:
In the Federal Register of January 27, 2006, FDA announced that a meeting of the Peripheral and Central Nervous System Drugs Advisory Committee would be held on March 7, 2006, from 8 a.m. to 5 p.m., and the open public hearing portion scheduled between approximately 1 p.m. and 2 p.m. On page 4593, in the third column, the Date and Time portion of the document is amended to read as follows:

Date and Time:
The meeting will be held on March 7 and 8, 2006, from 8 a.m. to 5 p.m.

Supplementary Information (continued):
On page 4594, in the first column, in the Procedure portion of the document, the third sentence is amended to read as follows:

Procedure:
Oral presentations from the public will be scheduled between approximately 1 p.m. and 5 p.m. on March 7, 2006.

Contact Person:
Sohail Mosaddegh, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, Rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: sohail.mosaddegh@fda.hhs.gov,

[ Original Notice ]